Sunitinib After Kidney Surgery — and for GIST: Two Different Settings

The four weeks of active treatment are when most side effects are most noticeable. Fatigue, hand-foot skin changes, and appetite loss tend to peak in the second and third weeks of the cycle. The two-week break allows some recovery, though you may still feel the effects early in that break. Side effects are not always worse each cycle — many people find them more manageable once they know what to expect. Tell your team if a cycle feels significantly worse than the last so they can adjust the plan.

Call the same day if you develop chest pain, breathlessness, a sudden severe headache, or any change in your vision — these need urgent review. Severe hand-foot skin reaction, where the skin is blistering, breaking down, or making it difficult to walk or use your hands, should also be reported the same day. Any bleeding that does not stop with simple pressure, significant swelling especially of the face, or a fever alongside other new symptoms should prompt an immediate call rather than a wait for the next appointment.

In the adjuvant setting after kidney surgery, there is no active tumour to measure, so your team uses scans at scheduled intervals to check that nothing has returned. The treatment is considered to be doing its job as long as you remain free of recurrence during and after the course. For GIST, response is assessed by imaging — usually a CT scan — looking at whether the tumour has shrunk, stayed stable, or grown. A tumour that stays stable on sunitinib is generally considered a response in advanced disease, not a failure.

Many people continue to work during treatment, particularly in less physically demanding roles. Fatigue is the most variable factor and is hard to predict before you start — give yourself permission to adjust your expectations cycle by cycle. Travel is possible but requires planning: ensure you have enough tablets for the full trip, know when your next blood test is due, and carry contact details for your team in case something changes while you are away. Tell your treating team about any extended travel plans so they can adjust your monitoring schedule if needed.

If sunitinib stops controlling the disease — shown by tumour growth on imaging — your oncologist will discuss what comes next. Further treatment options exist for advanced GIST after sunitinib, and a clinical trial may also be worth discussing depending on what is available for your situation. We do not yet have data that reliably predicts in advance who will respond to subsequent treatments, so the conversation about next steps is best had with your oncologist, who knows your full history. The important thing to know is that sunitinib stopping does not mean the conversation is over.

No. Sunitinib is a targeted therapy — specifically a tyrosine kinase inhibitor. It works by blocking proteins that tumour cells rely on to grow and form the new blood vessels that feed them, rather than by attacking all rapidly dividing cells the way chemotherapy does. Hair loss is not a typical side effect, and the pattern of side effects is different from classic chemotherapy. It is taken as a tablet at home on your prescribed schedule, not given as an infusion. Fatigue, skin changes, and blood pressure effects are more characteristic than the nausea and hair loss people associate with chemotherapy.